(GMRE) Global Medical REIT - Ratings and Ratios
Medical Facilities, Leasing
Dividends
| Dividend Yield | 3.98% |
| Yield on Cost 5y | 2.78% |
| Yield CAGR 5y | 1.23% |
| Payout Consistency | 97.3% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.4% |
| Value at Risk 5%th | 44.1% |
| Relative Tail Risk | -5.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.57 |
| Alpha | -28.54 |
| CAGR/Max DD | -0.10 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.584 |
| Beta | 0.630 |
| Beta Downside | 0.780 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.20% |
| Mean DD | 18.62% |
| Median DD | 18.10% |
Description: GMRE Global Medical REIT November 18, 2025
Global Medical REIT Inc. (GMRE) is a Maryland-incorporated, internally managed REIT that acquires and leases medical office buildings to physician groups and health systems, operating its assets through the Delaware limited partnership Global Medical REIT L.P.
The Company acts as the sole general partner of the Operating Partnership via its wholly-owned subsidiary Global Medical REIT GP LLC. As of September 30 2025, GMRE owned 92.14% of the partnership, with the remaining 7.86% held by LTIP unit participants and third-party limited partners who contributed properties or services for partnership units.
GMRE trades on the NYSE under the ticker “GMRE,” is classified as a common stock, and falls within the Health Care REIT sub-industry of the GICS classification system.
Key operational metrics that investors watch include a 96.5% occupancy rate across its 115+ facilities, FY 2024 funds-from-operations (FFO) of $0.34 per share, and a net debt-to-FFO leverage ratio of roughly 3.2×, reflecting a balance between growth acquisitions and financial discipline. The REIT’s performance is closely tied to macro drivers such as the aging U.S. population, which fuels demand for outpatient services, and the ongoing shift of care delivery from inpatient hospitals to ambulatory settings, both of which support long-term rental growth.
For deeper quantitative analysis, consider reviewing GMRE’s profile on the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (2.50m TTM) > 0 and > 6% of Revenue (6% = 8.88m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -3.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -11.18% (prev -462.7%; Δ 451.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 72.5m > Net Income 2.50m (YES >=105%, WARN >=100%) |
| Net Debt (721.5m) to EBITDA (83.2m) ratio: 8.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.4m) change vs 12m ago 408.9% (target <= -2.0% for YES) |
| Gross Margin 68.76% (prev 79.36%; Δ -10.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 11.76% (prev 10.98%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.81 (EBITDA TTM 83.2m / Interest Expense TTM 30.9m) >= 6 (WARN >= 3) |
Altman Z'' -1.25
| (A) -0.01 = (Total Current Assets 18.7m - Total Current Liabilities 35.2m) / Total Assets 1.27b |
| (B) -0.26 = Retained Earnings (Balance) -332.6m / Total Assets 1.27b |
| (C) 0.02 = EBIT TTM 24.9m / Avg Total Assets 1.26b |
| (D) -0.42 = Book Value of Equity -325.1m / Total Liabilities 767.4m |
| Total Rating: -1.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.32
| 1. Piotroski 1.0pt |
| 2. FCF Yield 1.17% |
| 3. FCF Margin 12.59% |
| 4. Debt/Equity 1.50 |
| 5. Debt/Ebitda 8.67 |
| 6. ROIC - WACC (= -2.87)% |
| 7. RoE 0.49% |
| 8. Rev. Trend 61.25% |
| 9. EPS Trend -48.55% |
What is the price of GMRE shares?
Over the past week, the price has changed by +0.58%, over one month by +8.86%, over three months by -7.32% and over the past year by -16.65%.
Is GMRE a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GMRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.3 | 27.6% |
| Analysts Target Price | 42.3 | 27.6% |
| ValueRay Target Price | 33.1 | -0.2% |
GMRE Fundamental Data Overview November 25, 2025
P/E Forward = 144.9275
P/S = 6.0374
P/B = 1.0492
P/EG = -26.28
Beta = 1.21
Revenue TTM = 148.0m USD
EBIT TTM = 24.9m USD
EBITDA TTM = 83.2m USD
Long Term Debt = 709.6m USD (from longTermDebt, last quarter)
Short Term Debt = 280.0k USD (from shortTermDebt, last quarter)
Debt = 728.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 721.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.60b USD (874.4m + Debt 728.7m - CCE 7.12m)
Interest Coverage Ratio = 0.81 (Ebit TTM 24.9m / Interest Expense TTM 30.9m)
FCF Yield = 1.17% (FCF TTM 18.6m / Enterprise Value 1.60b)
FCF Margin = 12.59% (FCF TTM 18.6m / Revenue TTM 148.0m)
Net Margin = 1.69% (Net Income TTM 2.50m / Revenue TTM 148.0m)
Gross Margin = 68.76% ((Revenue TTM 148.0m - Cost of Revenue TTM 46.2m) / Revenue TTM)
Gross Margin QoQ = 42.72% (prev 78.31%)
Tobins Q-Ratio = 1.25 (Enterprise Value 1.60b / Total Assets 1.27b)
Interest Expense / Debt = 1.12% (Interest Expense 8.18m / Debt 728.7m)
Taxrate = 2.14% (-108.0k / -5.06m)
NOPAT = 24.4m (EBIT 24.9m * (1 - 2.14%))
Current Ratio = 0.53 (Total Current Assets 18.7m / Total Current Liabilities 35.2m)
Debt / Equity = 1.50 (Debt 728.7m / totalStockholderEquity, last quarter 485.3m)
Debt / EBITDA = 8.67 (Net Debt 721.5m / EBITDA 83.2m)
Debt / FCF = 38.73 (Net Debt 721.5m / FCF TTM 18.6m)
Total Stockholder Equity = 510.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.20% (Net Income 2.50m / Total Assets 1.27b)
RoE = 0.49% (Net Income TTM 2.50m / Total Stockholder Equity 510.0m)
RoCE = 2.05% (EBIT 24.9m / Capital Employed (Equity 510.0m + L.T.Debt 709.6m))
RoIC = 2.18% (NOPAT 24.4m / Invested Capital 1.12b)
WACC = 5.05% (E(874.4m)/V(1.60b) * Re(8.34%) + D(728.7m)/V(1.60b) * Rd(1.12%) * (1-Tc(0.02)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 125.9%
[DCF Debug] Terminal Value 69.14% ; FCFE base≈36.7m ; Y1≈24.1m ; Y5≈11.0m
Fair Price DCF = 15.37 (DCF Value 206.0m / Shares Outstanding 13.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -48.55 | EPS CAGR: -18.74% | SUE: -0.07 | # QB: 0
Revenue Correlation: 61.25 | Revenue CAGR: 8.05% | SUE: 1.64 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=2.23 | Chg30d=-2.115 | Revisions Net=+0 | Growth EPS=-46.1% | Growth Revenue=+2.7%
Additional Sources for GMRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle